In addition, we found a statistically significant association between the presence of CYLD mutation and the accumulation of mutations per tumour (Supplementary Fig. 4c), suggesting that loss of CYLD catalytic activity may favour the accumulation of somatic mutations in human cancers by impairing DNA damage-induced p53 responses. The gene discussed is TP53; the disease is cancer.